Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen(®)

BACKGROUND: Filgrastim or methionyl-granulocyte colony-stimulating factor (Met-G-CSF), is a recombinant therapeutic protein widely used to treat severe neutropenia caused by myelosuppressive drugs in patients with nonmyeloid malignancies. In addition to its role in the regulation of granulopoiesis,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Crobu, Davide, Spinetti, Gaia, Schrepfer, Rodolfo, Tonon, Giancarlo, Jotti, Gloria Saccani, Onali, Pierluigi, Dedoni, Simona, Orsini, Gaetano, Di Stefano, Andrea
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3942296/
https://ncbi.nlm.nih.gov/pubmed/24555723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2050-6511-15-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items